3069.HK Flash News: Biotech sector surges 6% in morning session, Innovent Biologics leads heavyweight stocks

July 15th, the Hong Kong stock market was strong across the board this morning, with the biotech sector performing particularly well and leading the market significantly. As of 11:43 AM, the Hang Seng Biotech Index surged sharply, with a gain of approximately 6.29%, indicating a heated market atmosphere.

Several heavyweight stocks within the sector were driven by various news:

• Innovent Biologics (1801 HK, weight 0.09%): Innovent Biologics and Spero Therapeutics entered into an exclusive licensing agreement for IBI355 (a third-generation anti-CD40L monoclonal antibody, in Phase II preparation stage). Under the agreement, Spero will obtain the exclusive global rights to develop, research, manufacture, and commercialize SP001 (IBI355) outside Greater China. Innovent will receive an upfront payment of tens of millions of US dollars and milestone payments related to development, registration, and sales, with a total deal value of approximately $11 billion.

• Akeso Biopharma (9926 HK, weight 7.99%): The company recently announced a share repurchase plan. Alongside more than ten other Hong Kong-listed innovative pharmaceutical companies such as WuXi XDC and InnoBioPharma, Akeso has simultaneously signaled repurchases. The market is re-evaluating management's confidence in its own valuation based on this, coupled with rising expectations for the out-licensing of its bispecific antibody pipeline.

• Kelun-Biotech (6990 HK, weight 2.92%): The transaction value for out-licensing deals of China's innovative drug BD in the first half of 2026 approached one hundred billion US dollars, representing a significant year-on-year increase. As an ADC out-licensing target, the company continues to benefit, and the market is re-evaluating the clinical progress of its pipeline and the speed of realizing licensing income.

Important Information about the ChinaAMC Hang Seng Biotech ETF

Investing involves risks, including the potential loss of principal. Past performance is not indicative of future results. Before investing in the ChinaAMC Hang Seng Biotech ETF ("the Fund"), investors should read the Fund's offering documents, including the risk factors. You should not rely solely on this material to make investment decisions. Please note: • The Fund's investment objective is to provide investment returns that closely track the performance of the Hang Seng Biotech Index ("the Index") (before fees and expenses). • The Fund is passively managed. A decline in the Index is expected to result in a corresponding decline in the Fund's value. • The Fund's investment in equity securities is subject to general market risks. Its value may fluctuate due to various factors. • As the Index is a new index, the Fund may face higher risks compared to other exchange-traded funds tracking indices with longer operating histories. • The Fund tracks the performance of biotech companies and a specific region (i.e., Mainland China and Hong Kong), thus facing concentration risk, and its volatility is likely to exceed that of broadly diversified funds. • The Fund is subject to risks associated with the characteristics of biotech companies, such as having no operating revenue yet, generating net current liabilities, lower liquidity, higher volatility, reliance on intellectual property or patents, technological changes, increased regulations, and intense competition. • The Fund involves securities lending transaction risks, including the risk that the borrower may fail to return the securities on time or at all. • The Fund involves tracking error risk. • If cross-counter transfers of Fund units between two counters are suspended, and/or due to any restrictions on the services of securities brokers and Central Clearing and Settlement System participants, unit holders will only be able to trade their Fund units on one counter. The market prices of Fund units traded on different counters may vary significantly. • Fund unit holders will only receive distributions in HKD. Fund unit holders based in non-HKD currencies may bear the costs and expenses associated with foreign exchange conversion. • The Fund's base currency is HKD, but there are also Fund units traded in USD. Investors may need to bear additional costs or losses related to foreign currency fluctuations. • Generally, retail investors can only buy and sell the Fund's units on the Hong Kong Stock Exchange, and the trading price of the Fund's units on the Hong Kong Stock Exchange is affected by market factors, such as the supply and demand for the Fund's units. Therefore, the trading price of the Fund's units may trade at a significant premium or discount to the Fund's net asset value.

Sources:

• Innovent Biologics: Yahoo Finance, AASTOCKS, July 15, 2026, https://hk.finance.yahoo.com/news/%E4%BF%A1%E9%81%94%E7%94%9F%E7%89%A9-01801-hk-%E5%8D%87%E9%80%BE7-%E8%88%87spero-020815251.html

Unless otherwise specified, data is sourced from Bloomberg, ChinaAMC (Hong Kong), as of July 15, 2026.

Investing involves risks, including the possible loss of principal. Any forecasts, outlooks, or opinions contained herein are for your reference only and are not guaranteed to be realized. The information contained in this document reflects market conditions and our views as of the date of publication and is subject to change without notice. The issuer of this material is China Asset Management (Hong Kong) Limited. This material has not been reviewed by the Securities and Futures Commission of Hong Kong. For full details and risks of the mentioned fund, please refer to our official website and the fund's offering documents.